User profiles for Mohamed Ghaith Al Kuwari

Mohamed Ghaith Al-Kuwari

Sr Consultant PHCC and Clinical Professor College of Medicine , Qatar University
Verified email at phcc.gov.qa
Cited by 7762

[HTML][HTML] Effect of mRNA vaccine boosters against SARS-CoV-2 Omicron infection in Qatar

…, P Coyle, Z Al-Kanaani, E Al-Kuwari… - … England Journal of …, 2022 - Mass Medical Soc
Background Waning of vaccine protection against coronavirus disease 2019 (Covid-19)
and the emergence of the omicron (or B.1.1.529) variant of the severe acute respiratory …

[HTML][HTML] mRNA-1273 COVID-19 vaccine effectiveness against the B. 1.1. 7 and B. 1.351 variants and severe COVID-19 disease in Qatar

…, MG Al Kuwari, HE Al Romaihi, MH Al-Thani… - Nature medicine, 2021 - nature.com
The SARS-CoV-2 pandemic continues to be a global health concern. The mRNA-1273 (Moderna)
vaccine was reported to have an efficacy of 94.1% at preventing symptomatic COVID-…

[HTML][HTML] Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA. 1 and BA. 2 subvariants in Qatar

…, MR Hasan, Z Al-Kanaani, E Al-Kuwari… - Nature …, 2022 - nature.com
SARS-CoV-2 Omicron BA.1 and BA.2 subvariants are genetically divergent. We conducted
a matched, test-negative, case-control study to estimate duration of protection of the second …

[HTML][HTML] BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar

…, MG Al Kuwari, HE Al Romaihi, AA Butt, MH Al-Thani… - Nature medicine, 2021 - nature.com
With the global expansion of the highly transmissible SARS-CoV-2 Delta (B.1.617.2) variant,
we conducted a matched test-negative case–control study to assess the real-world …

[HTML][HTML] SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy

…, MG Al Kuwari, HE Al Romaihi, MH Al-Thani… - …, 2021 - thelancet.com
Background Reinfection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
has been documented, raising public health concerns. SARS-CoV-2 reinfections were …

Duration of immune protection of SARS-CoV-2 natural infection against reinfection

…, MR Hasan, Z Al-Kanaani, E Al-Kuwari… - Journal of Travel …, 2022 - academic.oup.com
Background The future of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
pandemic hinges on virus evolution and duration of immune protection of natural infection …

Association of prior SARS-CoV-2 infection with risk of breakthrough infection following mRNA vaccination in Qatar

…, MG Al Kuwari, AA Butt, HE Al Romaihi, MH Al-Thani… - Jama, 2021 - jamanetwork.com
Importance The effect of prior SARS-CoV-2 infection on vaccine protection remains poorly
understood. Objective To assess protection from SARS-CoV-2 breakthrough infection after …

[HTML][HTML] Long-term COVID-19 booster effectiveness by infection history and clinical vulnerability and immune imprinting: a retrospective population-based cohort study

…, MR Hasan, Z Al-Kanaani, E Al-Kuwari… - The Lancet Infectious …, 2023 - thelancet.com
Background Long-term effectiveness of COVID-19 mRNA boosters in populations with different
previous infection histories and clinical vulnerability profiles is inadequately understood. …

[HTML][HTML] Protection from previous natural infection compared with mRNA vaccination against SARS-CoV-2 infection and severe COVID-19 in Qatar: a retrospective …

…, MR Hasan, Z Al-Kanaani, E Al-Kuwari… - The Lancet …, 2022 - thelancet.com
Background Understanding protection conferred by natural SARS-CoV-2 infection versus
COVID-19 vaccination is important for informing vaccine mandate decisions. We compared …

[HTML][HTML] Relative infectiousness of SARS-CoV-2 vaccine breakthrough infections, reinfections, and primary infections

…, HA Al-Khatib, Z Al-Kanaani, E Al-Kuwari… - Nature …, 2022 - nature.com
SARS-CoV-2 breakthrough infections in vaccinated individuals and in those who had a prior
infection have been observed globally, but the transmission potential of these infections is …